STOCK TITAN

Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rein Therapeutics (RNTX) reported preliminary blinded Phase 2 RENEW lung-function observations in idiopathic pulmonary fibrosis alongside third-quarter 2026 financial results. Among 24 evaluable patients, 33% improved in forced vital capacity, a measure of exhaled air volume, at Week 12; changes ranged from a 338 ml improvement to a 349 ml decline. Results pool LTI-03 and placebo recipients and do not establish a treatment effect. No serious adverse events assessed as treatment-related were reported; 92% remained on or completed the study.

Enrollment reached 90 of approximately 120 patients. Rein expects topline results in 2027 and its $36.5 million in cash, cash equivalents and marketable securities to fund operations into the first quarter of 2028. Third-quarter net loss narrowed to $5.537 million from $5.581 million a year earlier; research spending rose while administrative expenses fell.

Loading...
Loading translation...
14 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointRENEW enrollment reached 75%, with 90 of approximately 120 patients randomized; Rein reports enrollment ahead of schedule.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Rein expects $36.5 million in liquidity to fund operations into first-quarter 2028, through Phase 2 completion.
  • Minor pointWeek 12 lung function improved in 33% (8 of 24) of evaluable patients across blinded treatment groups.
  • Minor pointWeek 12 FVC declined no more than 5.7% in 46% (11 of 24) of evaluable patients.
  • Minor pointBlinded safety observations showed no serious adverse events assessed as treatment-related as of the interim cutoff.
9 minor points
  • Minor pointStudy retention reached 92% of enrolled participants remaining on or completing the study.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Rein remains on track to report topline RENEW results in 2027.
  • Minor pointThird-quarter administrative expenses fell to $2.624 million from $3.811 million a year earlier.
  • Minor pointThird-quarter net loss narrowed to $5.537 million from $5.581 million; loss per share narrowed to $0.06 from $0.21.
  • Minor pointNine-month administrative expenses fell to $7.219 million from $8.944 million a year earlier.
  • Minor pointNine-month net loss narrowed to $17.750 million from $17.904 million; loss per share narrowed to $0.29 from $0.74.
  • Minor pointThird-quarter other income, net, reached $1.462 million, versus $89,000 in other expense a year earlier.
  • Minor pointNine-month other income, net, increased to $555,000 from $68,000 a year earlier.
  • Minor pointTotal liabilities decreased to $6.658 million at September 30, 2026, from $7.240 million at December 31, 2025.

Negative

  • Major pointCommon shares outstanding increased to 86,267,032 at September 30, 2026, from 27,550,222 at December 31, 2025.
  • Moderate pointPreliminary results remain blinded and pooled, preventing treatment-effect conclusions or comparisons between LTI-03 and placebo.
  • Moderate pointThird-quarter research expenses increased to $4.375 million from $1.681 million a year earlier.
  • Moderate pointThird-quarter operating loss widened to $6.999 million from $5.492 million a year earlier.
  • Minor pointWeek 12 FVC declined more than 5.7% in 21% (5 of 24) of evaluable patients.
3 minor points
  • Minor pointAdverse events included cough, the most frequently reported event, generally mild in severity.
  • Minor pointNine-month research expenses increased to $11.086 million from $9.028 million a year earlier.
  • Minor pointNine-month operating loss widened to $18.305 million from $17.972 million a year earlier.

News Explained

The balance sheet reports 86,267,032 common shares issued and outstanding on September 30, 2026, versus 27,550,222 on December 31, 2025; holders whose share counts stayed fixed therefore represented a smaller fraction of the company’s common shares.

Key Figures

Evaluable patients: 24 patients Patients with FVC improvement: 33% FVC decline no more than 5.7%: 46% +5 more
Evaluable patients
24 patients
Patients with evaluable baseline and Week 12 FVC measurements
Patients with FVC improvement
33%
Blinded, pooled Week 12 observations; 8 of 24 patients
FVC decline no more than 5.7%
46%
Blinded, pooled Week 12 observations; 11 of 24 patients
FVC decline greater than 5.7%
21%
Blinded, pooled Week 12 observations; 5 of 24 patients
Trial enrollment
90 patients randomized
75% of planned enrollment; approximately 120 patients planned
Cash, equivalents and marketable securities
$36.5 million
As of September 30, 2026; expected to fund operations into Q1 2028
Research and development expenses
$4.4 million
Third quarter 2026, compared with $1.7 million in the prior-year period
Net loss
$5.5 million
Third quarter 2026, compared with $5.6 million in the prior-year period

Historical Context

1 past event · Latest: Aug 14
1 event
  1. Aug 14

    Q2 earnings

    24h Move
    +2.4%

    RENEW enrollment exceeded 25%, and a $57.5 million offering funded trial operations into Q1 2028.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

forced vital capacity, idiopathic pulmonary fibrosis, hazard ratio, placebo-controlled
4 terms
forced vital capacity medical
"The preliminary analysis included 24 patients with evaluable baseline and Week 12 forced vital capacity (FVC) measurements."
The amount of air a person can forcefully breathe out after taking the deepest breath possible; think of it as how much air you can squeeze out of a balloon in one hard blow. It matters to investors because it’s a common, objective measure used in clinical trials and patient monitoring for respiratory drugs, devices and treatments—changes in this number can signal whether a therapy works, affecting regulatory approval, sales and company value.
idiopathic pulmonary fibrosis medical
"in patients with idiopathic pulmonary fibrosis (IPF)."
Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.
hazard ratio medical
"the threshold that best distinguished higher mortality risk (adjusted hazard ratio 2.6;"
A hazard ratio is a way scientists compare the chance of something happening over time between two groups, like patients taking different medicines. If the ratio is high, it means one group is more likely to experience the event sooner or more often, which helps determine how effective a treatment is or how risky a situation might be.
placebo-controlled medical
"The RENEW study is a randomized, placebo-controlled Phase 2 trial"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • 33% of evaluable patients demonstrated improvement over baseline in forced vital capacity (FVC) at Week 12
  • From baseline, change in FVC ranged from an improvement of 338 ml to a decline of 349 ml at Week 12
  • Low discontinuation rates, and favorable safety and tolerability observed across placebo and treatment groups, with no serious adverse events assessed as related to study treatment
  • Study has achieved 75% enrollment, with 90 patients randomized to date; on track to report topline data in 2027

AUSTIN, Texas, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced preliminary blinded twelve-week observations from the ongoing RENEW Phase 2 trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic pulmonary fibrosis (IPF). The Company also reported financial results for the third quarter ended September 30, 2026.

“During the third quarter, we continued to make rapid progress in our Phase 2 RENEW trial for LTI-03 supported by strong enrollment and investigator enthusiasm,” said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. “As we continue to enroll patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need. We remain committed to advancing the study toward completion and look forward to reporting unblinded topline data in 2027.”

Third Quarter 2026 and Recent Business Updates

Clinical Updates
The RENEW study is a randomized, placebo-controlled Phase 2 trial evaluating inhaled LTI-03 in patients with IPF. The trial remains blinded while enrollment continues. The preliminary analysis included 24 patients with evaluable baseline and Week 12 forced vital capacity (FVC) measurements.

  • Blinded outcomes consistent with expectations; FVC change at Week 12 indicates encouraging distribution:
    • At Week 12, preliminary blinded lung function observations included:
      • 33% of patients (8 of 24) demonstrated an improvement in FVC from baseline.
      • 46% of patients (11 of 24) experienced an FVC decline of no more than 5.7%, a threshold below which some studies have indicated a greater than 2X likelihood of progression to lung transplant or death.
      • 21% of patients (5 of 24) experienced an FVC decline in FVC from baseline of more than 5.7%.
    • These observations represent pooled results across patients randomized to placebo or one of two LTI-03 dose levels. Treatment assignments remain blinded, and the findings do not establish a treatment effect or allow comparisons between LTI-03 and placebo.

Figure 1

Figure 1: Blinded, pooled sponsor data (LTI-03 and placebo participants combined). N=24: participants with a Week 12 FVC result. Change in FVC from baseline to Week 12 calculated as a percentage of each participant’s own baseline. Baseline was calculated as the mean of the qualifying Screening and Day 1 pre-dose values. Groupings are descriptive and were not pre-specified. These thresholds were used to describe the distribution of blinded, pooled data; they do not predict outcomes for RENEW participants and cannot show a treatment effect. The 5.7% threshold is drawn from an individual participant data meta-analysis of the placebo arms of 12 IPF trial cohorts, in which a relative decline in FVC of more than 5.7% over 3 months was the threshold that best distinguished higher mortality risk (adjusted hazard ratio 2.6; Khan et al., Am J Respir Crit Care Med 2022). At a stricter 5% line, 75% (18 of 24) improved or declined less than 5%. The bar runs from the largest individual gain to the largest individual decline in FVC at Week 12: the full range, not a confidence interval. Not drawn to scale. These are single-participant values and cannot show a treatment effect.

  • Favorable safety and tolerability profile:
    • Preliminary blinded safety observations from the ongoing RENEW trial suggest a favorable safety and tolerability profile.
    • No serious adverse events related to study treatment have been reported as of the interim data cutoff.
    • Adverse events have been predominantly mild or moderate, with cough representing the most frequently reported adverse event and generally mild in severity.
    • Low rates of discontinuation, with 92% of enrolled participants remaining on or completing the study.
    • The trial remains blinded, and treatment-specific safety and tolerability will be further characterized as additional data become available.
  • On track to report topline data in 2027: As of November, Rein has achieved 75% of the trial’s planned enrollment, with 90 out of approximately 120 patients randomized to date across the United States, United Kingdom, Australia, Germany and Poland. Enrollment is tracking ahead of schedule and the Company remains on track to report topline data in 2027.

“Blinded interim data from our ongoing Phase 2 RENEW trial provides an early look at the safety, tolerability and lung function trends we are observing across the study population. The improvements in FVC from baseline observed in 33% of evaluable patients is particularly encouraging, as improvements in lung function are not expected in this patient population,” said Cory Hogaboam, Ph.D., Chief Scientific Officer. “In addition to the lung function improvements we are seeing in the study, adverse events across all patients have been mild to moderate, with no serious adverse events attributable to the drug and low discontinuation rates, with 92% of participants remaining on or completing the study. While the study remains blinded, these observations collectively strengthen our belief that LTI-03 has the potential to transform the treatment landscape for IPF.”

Third Quarter 2026 Financial Results

  • Cash position: Cash, cash equivalents and marketable securities were $36.5 million as of September 30, 2026. The Company’s cash, cash equivalents and marketable securities as of September 30, 2026 are expected to fund its operations into the first quarter of 2028 through the completion of the Phase 2 RENEW clinical trial of LTI-03.

  • R&D expenses: Research and development expenses were $4.4 million for the quarter ended September 30, 2026, compared to $1.7 million for the comparable prior year period. The increase of $2.7 million was primarily due to the increased spending on the RENEW phase 2 clinical trial versus the prior year when the FDA imposed a clinical hold on LTI-03, which was lifted in October 2025.

  • G&A expenses: General and administrative expenses were $2.6 million for the quarter ended September 30, 2026, compared to $3.8 million for the comparable prior year period. The decrease was primarily due to decreased professional fees.

  • Net loss: Net loss was $5.5 million for the quarter ended September 30, 2026, compared to $5.6 million for the comparable prior year period.

About LTI-03
LTI-03 is a first-in-class, investigational, inhaled peptide therapy derived from caveolin-1 biology, a key regulator of cellular signaling pathways involved in fibrosis, epithelial injury and tissue repair. LTI-03 is designed to inhibit profibrotic signaling while protecting alveolar epithelial cells that are important for maintaining and repairing lung tissue. The drug’s dual mechanism is intended to address both progressive lung scarring and epithelial dysfunction, two important features of IPF. LTI-03 received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration for IPF.

About the Phase 2 RENEW Trial
RENEW is an ongoing randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to evaluate the safety, tolerability and efficacy of inhaled LTI-03 in patients with IPF. The study is expected to enroll approximately 120 patients across clinical sites in the United States, United Kingdom, Australia, Poland, Germany, Bulgaria, and Romania. Participants are randomized to receive one of two LTI-03 dose levels or placebo over a 24-week treatment period. The primary endpoint is safety and tolerability as measured by the incidence of treatment-emergent adverse events. The secondary endpoints are efficacy assessments, including change from baseline in FVC, quantitative high-resolution computed tomography imaging and exploratory biomarkers associated with epithelial injury and fibrosis. The Company expects the trial to remain blinded throughout enrollment and patient follow-up, and to report topline results in 2027. For additional details, please refer to www.clinicaltrials.gov (identifier: NCT06968845).

About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. Rein’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements of Rein Therapeutics, Inc. (“Rein”, the “Company”, “we”, “our” or “us”) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the development of LTI-03, the design, conduct and expected results of the Phase 2 RENEW trial, the potential clinical benefits of LTI-03, future development milestones and the Company’s financial resources. We use words such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: (i) the risk that the Company may not be able to successfully continue its Phase 2 clinical trials of LTI-03; (ii) the risk that the Company may not report topline data derived from its Phase 2 trial in 2027 or, if it does, the risk that the data may not support or validate our expectations concerning the potential benefits of LTI-03; (iii) success in early phases of pre-clinical and clinical trials do not ensure later clinical trials will be successful; (iv) the risk that preliminary blinded interim observations may not predict subsequent or final study results; (v) the fact that the lung function observations described in this release are pooled across randomized treatment groups and cannot establish efficacy, dose response or superiority to placebo; (vi) the fact that the 5.7% FVC decline threshold is descriptive and is not a validated Week-12 measure of treatment response; (vii) the fact that preliminary adverse-event causality assessments may change as additional data become available; and (viii) the risk that the Company’s present cash and cash equivalents may not be sufficient to fund the Company’s operations into the first quarter of 2028 and (v) those other risks disclosed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 26, 2026, and in subsequent filings that the Company makes with the SEC. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Rein Therapeutics Investor Relations & Media Contact:
Investor Relations
IR@ReinTx.com


REIN THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share data)
       
  September 30,
2026
  December 31,
2025
 
Assets      
Current assets:      
Cash and cash equivalents $943  $3,215 
Short-term investments  34,550   — 
Prepaid expenses and other current assets  1,292   1,111 
Total current assets  36,785   4,326 
Goodwill  6,330   6,330 
Intangible assets  13,500   13,500 
Long-term investments  994   — 
Other non-current assets  1,821   2 
Total assets $59,430  $24,158 
Liabilities, Convertible Preferred Stock and Stockholders’ Equity      
Current liabilities:      
Accounts payable $3,199  $3,976 
Accrued expenses and other current liabilities  2,399   2,204 
Total current liabilities  5,598   6,180 
Deferred tax liability  1,060   1,060 
Total liabilities  6,658   7,240 
Commitments and contingencies (Note 13)      
Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at September 30, 2026 and at December 31, 2025; 24,610 shares issued and 12,232 shares outstanding at September 30, 2026 and at December 31, 2025  45,005   45,005 
Stockholders’ equity:      
Common stock, $0.001 par value; 200,000,000 shares and 100,000,000 authorized at September 30, 2026 and at December 31, 2025, respectively; 86,267,032 shares and 27,550,222 shares issued and outstanding at September 30, 2026 and at December 31, 2025, respectively  172   113 
Additional paid-in capital  426,731   373,133 
Accumulated other comprehensive loss  (115)  (62)
Accumulated deficit  (419,021)  (401,271)
Total liabilities, convertible preferred stock and stockholders’ equity $59,430  $24,158 
         


REIN THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share data)
       
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
  2026  2025  2026  2025 
Revenue $—  $—  $—  $— 
Operating expenses:            
Research and development  4,375   1,681   11,086   9,028 
General and administrative  2,624   3,811   7,219   8,944 
Total operating expenses  6,999   5,492   18,305   17,972 
Loss from operations  (6,999)  (5,492)  (18,305)  (17,972)
Other (expense) income, net  1,462   (89)  555   68 
Net loss $(5,537) $(5,581) $(17,750) $(17,904)
Net loss per share—basic and diluted $(0.06) $(0.21) $(0.29) $(0.74)
Weighted average common shares outstanding—basic and diluted  88,325,917   26,361,386   62,134,091   24,171,173 
Comprehensive loss:            
Net loss $(5,537) $(5,581) $(17,750) $(17,904)
Other comprehensive loss:            
Unrealized (loss) gain on investments, net of tax of $0  (45)  —   (57)  (33)
Foreign currency translation adjustments  (1)  —   4   7 
Total other comprehensive loss  (46)  —   (53)  (26)
Total comprehensive loss $(5,583) $(5,581) $(17,803) $(17,930)
                 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/22b5e69b-3a1b-4989-b1a9-5cc386743bf1


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rein Therapeutics' preliminary RENEW results show for LTI-03?

At Week 12, 33% (8 of 24) of evaluable patients improved in forced vital capacity from baseline. The observations combine placebo recipients and patients receiving either of two LTI-03 doses. Treatment assignments remain blinded, so these results cannot establish a treatment effect or support comparisons with placebo.

When does Rein Therapeutics expect RENEW results, and how long will its cash last?

Rein expects topline results in 2027 and its September 30, 2026 cash, cash equivalents and marketable securities of $36.5 million to fund operations into the first quarter of 2028. That expected runway extends through completion of the Phase 2 RENEW trial.

How is Rein Therapeutics' Phase 2 RENEW trial designed?

RENEW randomizes patients with idiopathic pulmonary fibrosis to two LTI-03 dose levels or placebo over a 24-week treatment period. Its primary endpoint is safety and tolerability, measured by treatment-emergent adverse events. Secondary assessments include lung function, quantitative high-resolution computed tomography imaging and exploratory biomarkers. Rein expects the study to remain blinded throughout enrollment and patient follow-up.

Does the 5.7% FVC threshold predict outcomes for Rein Therapeutics' RENEW participants?

The 5.7% threshold does not predict outcomes for RENEW participants. It comes from a separate analysis of placebo arms in 12 idiopathic pulmonary fibrosis trial cohorts. RENEW's groupings were descriptive and not pre-specified; the blinded, pooled observations cannot demonstrate a treatment effect.

Keep reading